James Tyree Net Worth

The estimated Net Worth of James L Tyree is at least $9.7 Million dollars as of 21 May 2019. Mr. Tyree owns over 8,421 units of ChemoCentryx stock worth over $326,941 and over the last 15 years he sold CCXI stock worth over $9,073,770. In addition, he makes $302,695 as Independent Director at ChemoCentryx.

Mr. Tyree CCXI stock SEC Form 4 insider trading

James has made over 27 trades of the ChemoCentryx stock since 2006, according to the Form 4 filled with the SEC. Most recently he exercised 8,421 units of CCXI stock worth $77,894 on 21 May 2019.

The largest trade he’s ever made was exercising 98,831 units of ChemoCentryx stock on 2 February 2009 worth over $4,548,203. On average, James trades about 10,625 units every 110 days since 2005. As of 21 May 2019 he still owns at least 35,345 units of ChemoCentryx stock.

You can see the complete history of Mr. Tyree stock trades at the bottom of the page.

James Tyree biography

James L. Tyree is an Independent Director of ChemoCentryx, Inc., since June 5, 2012. Mr. Tyree has served as co-founder, chairman and managing partner of Tyree & D’Angelo Partners, a private equity investment firm. Prior to founding Tyree & D’Angelo Partners, Mr. Tyree was Executive Vice President and President of Abbott Biotech Ventures, a subsidiary of Abbott Laboratories focused on investments in early stage biotechnology companies. Prior to that, Mr. Tyree held numerous executive positions at Abbott, including Executive Vice President Global Pharmaceuticals, Senior Vice President Global Nutrition, Corporate Vice President Pharmaceutical and Nutritional Products Group Business Development and Divisional Vice President and General Manager, Japan. Prior to rejoining Abbott in 1997, Mr. Tyree was the President of SUGEN, Inc., and held management positions in Bristol-Myers Squibb, Pfizer and Abbott. Mr. Tyree currently serves as a director of Assertio Therapeutics, Inc. Mr. Tyree earned Bachelor’s Degrees in Psychology and Forensic Studies and a Master’s Degree in Business Administration from Indiana University.

What is the salary of James Tyree?

As the Independent Director of ChemoCentryx, the total compensation of James Tyree at ChemoCentryx is $302,695. There are 4 executives at ChemoCentryx getting paid more, with Thomas Schall having the highest compensation of $3,862,220.

How old is James Tyree?

James Tyree is 66, he’s been the Independent Director of ChemoCentryx since 2012. There are 2 older and 7 younger executives at ChemoCentryx. The oldest executive at ChemoCentryx, Inc. is Henry McKinnell, 76, who is the Independent Director.

What’s James Tyree’s mailing address?

James’s mailing address filed with the SEC is 951 GATEWAY BLVD., , SOUTH SAN FRANCISCO, CA, 94080.

Insider trading at ChemoCentryx

Over the last 8 years, insiders at ChemoCentryx have traded over $105,144,091 worth of ChemoCentryx stock and bought 3,156,105 units worth $19,355,439 . The most active insider traders include Plc Glaxosmithkline, Partners L P/Ilbiotechnolog…, and Partners L P/Ilbiotechnolog…. On average, ChemoCentryx executives and independent directors trade stock every 13 days with the average trade being worth of $712,010. The most recent stock trade was executed by Susan M Kanaya on 20 October 2019, trading 33,334 units of CCXI stock currently worth $333,340.

What does ChemoCentryx do?

ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.

What does ChemoCentryx’s logo look like?

Complete history of Mr. Tyree stock trades at ChemoCentryx, Innoviva, and Abbott Laboratories

ChemoCentryx executives and stock owners

ChemoCentryx executives and other stock owners filed with the SEC include:

  • Thomas Schall, Chairman of the Board, President, Chief Executive Officer
  • Susan Kanaya, Chief Financial Officer, Executive Vice President, Chief Administrative Officer, Secretary, IR Contact Officer
  • Markus Cappel, Chief Business Officer, Treasurer
  • Rajinder Singh, Senior Vice President – Research
  • James Tyree, Independent Director
  • Thomas Edwards, Independent Director
  • Henry McKinnell, Independent Director
  • Joseph Feczko, Independent Director
  • Geoffrey Parker, Independent Director
  • Rita Jain, Independent Director
  • Roger C Lucas, Director
  • Petrus Bekker, SVP of Medical & Clinical
  • Partners L P/Ilbiotechnolog…,
  • Pui San Kwan, Principal Acctg Officer
  • William Fairey, Chief Operating Officer
  • Plc Glaxosmithkline, 10% owner
  • Edward Penhoet, Director
  • Ira Klein, Director
  • Partners L P/Ilbiotechnolog…,
  • Anne Marie Duliege, EVP, Chief of Strategic Dev.
  • Israel Charo, SVP, Research
  • Juan C. Jaen, SVP, Drug Discovery & CSO
  • Partners L P/Ilbvf Investme…,
  • Corp /Mn/ Techne, 10% owner
  • Advisors Llcorbimed Capital…,
  • Rishi Gupta, Director